Suppr超能文献

胃肠道癌靶向治疗的新兴趋势:利用肿瘤微环境、免疫因素和代谢组学见解。

Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights.

机构信息

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center at Omaha, Omaha, Nebraska.

Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida.

出版信息

Gastroenterology. 2024 Oct;167(5):867-884. doi: 10.1053/j.gastro.2024.05.005. Epub 2024 May 15.

Abstract

Gastrointestinal (GI) cancers are the leading cause of new cancer cases and cancer-related deaths worldwide. The treatment strategies for patients with GI tumors have focused on oncogenic molecular profiles associated with tumor cells. Recent evidence has demonstrated that the tumor cell functions are modulated by its microenvironment, compromising fibroblasts, extracellular matrices, microbiome, immune cells, and the enteric nervous system. Along with the tumor microenvironment components, alterations in key metabolic pathways have emerged as a hallmark of tumor cells. From these perspectives, this review will highlight the functions of different cellular components of the GI tumor microenvironment and their implications for treatment. Furthermore, we discuss the major metabolic reprogramming in GI tumor cells and how understanding metabolic rewiring could lead to new therapeutic strategies. Finally, we briefly summarize the targeted agents currently being studied in GI cancers. Understanding the complex interplay between tumor cell-intrinsic and -extrinsic factors during tumor progression is critical for developing new therapeutic strategies.

摘要

胃肠道(GI)癌症是全球新癌症病例和癌症相关死亡的主要原因。GI 肿瘤患者的治疗策略集中于与肿瘤细胞相关的致癌分子特征。最近的证据表明,肿瘤细胞的功能受到其微环境的调节,包括成纤维细胞、细胞外基质、微生物组、免疫细胞和肠神经系统。除了肿瘤微环境成分外,关键代谢途径的改变也成为肿瘤细胞的一个标志。从这些角度来看,本综述将强调 GI 肿瘤微环境中不同细胞成分的功能及其对治疗的意义。此外,我们还讨论了 GI 肿瘤细胞中主要的代谢重编程,以及了解代谢重编程如何导致新的治疗策略。最后,我们简要总结了目前正在 GI 癌症中研究的靶向药物。了解肿瘤进展过程中肿瘤细胞内在和外在因素之间的复杂相互作用对于开发新的治疗策略至关重要。

相似文献

1
Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights.
Gastroenterology. 2024 Oct;167(5):867-884. doi: 10.1053/j.gastro.2024.05.005. Epub 2024 May 15.
2
Targeting extracellular matrix interaction in gastrointestinal cancer: Immune modulation, metabolic reprogramming, and therapeutic strategies.
Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189225. doi: 10.1016/j.bbcan.2024.189225. Epub 2024 Nov 25.
3
Targeting the immune milieu in gastrointestinal cancers.
J Gastroenterol. 2020 Oct;55(10):909-926. doi: 10.1007/s00535-020-01710-x. Epub 2020 Aug 3.
4
The nerve cells in gastrointestinal cancers: from molecular mechanisms to clinical intervention.
Oncogene. 2024 Jan;43(2):77-91. doi: 10.1038/s41388-023-02909-x. Epub 2023 Dec 11.
5
The gastrointestinal tumor microenvironment.
Gastroenterology. 2013 Jul;145(1):63-78. doi: 10.1053/j.gastro.2013.03.052. Epub 2013 Apr 10.
6
The Importance of Cancer Stem Cells in Gastrointestinal Cancers.
Crit Rev Oncog. 2019;24(1):55-59. doi: 10.1615/CritRevOncog.2018029633.
8
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance.
Drug Resist Updat. 2024 Nov;77:101125. doi: 10.1016/j.drup.2024.101125. Epub 2024 Aug 6.
10
Association between Metabolic Reprogramming and Immune Regulation in Digestive Tract Tumors.
Oncol Res Treat. 2024;47(6):273-286. doi: 10.1159/000538659. Epub 2024 Apr 18.

引用本文的文献

1
Global research trends in tryptophan metabolism and cancer: a bibliometric and visualization analysis (2005-2024).
Front Oncol. 2025 Jul 1;15:1621666. doi: 10.3389/fonc.2025.1621666. eCollection 2025.
4
Computational analysis of DEHP's oncogenic role in colorectal cancer.
Discov Oncol. 2025 May 21;16(1):848. doi: 10.1007/s12672-025-02616-x.
5
Nanomaterials in the diagnosis and treatment of gastrointestinal tumors: New clinical choices and treatment strategies.
Mater Today Bio. 2025 Apr 19;32:101782. doi: 10.1016/j.mtbio.2025.101782. eCollection 2025 Jun.
6
Clinical analysis of lymphoma with malignant solid tumor simultaneously: a retrospective case series.
Diagn Pathol. 2025 Apr 26;20(1):54. doi: 10.1186/s13000-025-01653-y.
8
Gut microbiota and gastrointestinal tumors: insights from a bibliometric analysis.
Front Microbiol. 2025 Apr 8;16:1558490. doi: 10.3389/fmicb.2025.1558490. eCollection 2025.
9
Inflammation and cancer: molecular mechanisms and clinical consequences.
Front Oncol. 2025 Mar 17;15:1564572. doi: 10.3389/fonc.2025.1564572. eCollection 2025.

本文引用的文献

1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Cancer-Associated Fibroblasts in Esophageal Cancer.
Cell Mol Gastroenterol Hepatol. 2024;17(5):687-695. doi: 10.1016/j.jcmgh.2024.01.008. Epub 2024 Jan 19.
3
Targeting the lactic acid metabolic pathway for antitumor therapy.
Mol Ther Oncolytics. 2023 Oct 31;31:100740. doi: 10.1016/j.omto.2023.100740. eCollection 2023 Dec 19.
6
A Quick Guide to CAF Subtypes in Pancreatic Cancer.
Cancers (Basel). 2023 May 4;15(9):2614. doi: 10.3390/cancers15092614.
8
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
10
Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma.
Cell Mol Gastroenterol Hepatol. 2023;15(4):985-999. doi: 10.1016/j.jcmgh.2023.01.006. Epub 2023 Jan 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验